Notably, raising growth capital and strategic partnering remain the most common planned activities, while relatively few ...

Just a few months after being formed, China's Funnel Biosciences has signed a $2 billion-plus partnership with Third Rock ...

UK-based startup Oyster Therapeutics has raised $60 million in first-round financing that will be used to advance its tau ...

Hims & Hers is also offering compounded formulations of other unapproved peptides, including sermorelin, which some people ...

The FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to the label of their products for a rare eye ...

Asundexian has been approved by the FDA under the Sunharbo brand name for use in combination with antiplatelet therapy to ...

The takeover deal – worth up to $1.15 billion including $550 million in upfront cash – will upgrade the Dutch biotech's ...

Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies Zepbound and Foundayo sold ...

The comprehensive failure of Lp (a)HORIZON has cast a pall over the prospects for other Lp (a)-targeting drugs, including ...

The WuXi agreement gives Fresenius "full strategic flexibility" to choose which biosimilar candidates to develop and gives ...

The one-year-old start-up is the latest to receive financial backing from the UK government's £500 million Sovereign AI ...